Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

The ninth ENBDC Weggis meeting: growth and in-depth characterisation of normal and neoplastic breast cells.

Wiese KE, Amante RJ, Vivanco MD, Bentires-Alj M, Iggo RD.

Breast Cancer Res. 2017 Aug 22;19(1):96. doi: 10.1186/s13058-017-0891-9.

2.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

3.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

4.

MICADo - Looking for Mutations in Targeted PacBio Cancer Data: An Alignment-Free Method.

Rudewicz J, Soueidan H, Uricaru R, Bonnefoi H, Iggo R, Bergh J, Nikolski M.

Front Genet. 2016 Dec 8;7:214. doi: 10.3389/fgene.2016.00214. eCollection 2016.

5.

Cluster Analysis of p53 Binding Site Sequences Reveals Subsets with Different Functions.

Lim JH, Latysheva NS, Iggo RD, Barker D.

Cancer Inform. 2016 Oct 25;15:199-209. eCollection 2016.

6.

The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours.

Richard E, Grellety T, Velasco V, MacGrogan G, Bonnefoi H, Iggo R.

J Pathol. 2016 Nov;240(3):256-261. doi: 10.1002/path.4772. Epub 2016 Sep 29.

PMID:
27447842
7.

Erratum to: Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells.

Verbeke S, Richard E, Monceau E, Schmidt X, Rousseau B, Velasco V, Bernard D, Bonnefoi H, MacGrogan G, Iggo RD.

Breast Cancer Res. 2015 Sep 16;17(1):126. doi: 10.1186/s13058-015-0612-1.

8.

Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.

Quenel-Tueux N, Debled M, Rudewicz J, MacGrogan G, Pulido M, Mauriac L, Dalenc F, Bachelot T, Lortal B, Breton-Callu C, Madranges N, de Lara CT, Fournier M, Bonnefoi H, Soueidan H, Nikolski M, Gros A, Daly C, Wood H, Rabbitts P, Iggo R.

Br J Cancer. 2015 Aug 11;113(4):585-94. doi: 10.1038/bjc.2015.247. Epub 2015 Jul 14.

9.

Lentiviral transduction of mammary epithelial cells.

Iggo R, Richard E.

Methods Mol Biol. 2015;1293:137-60. doi: 10.1007/978-1-4939-2519-3_8.

PMID:
26040686
10.

Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response.

Chapellier M, Bachelard-Cascales E, Schmidt X, Clément F, Treilleux I, Delay E, Jammot A, Ménétrier-Caux C, Pochon G, Besançon R, Voeltzel T, Caron de Fromentel C, Caux C, Blay JY, Iggo R, Maguer-Satta V.

Stem Cell Reports. 2015 Feb 10;4(2):239-54. doi: 10.1016/j.stemcr.2014.12.007. Epub 2015 Jan 15.

11.

Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells.

Verbeke S, Richard E, Monceau E, Schmidt X, Rousseau B, Velasco V, Bernard D, Bonnefoi H, MacGrogan G, Iggo RD.

Breast Cancer Res. 2014 Dec 20;16(6):504. doi: 10.1186/s13058-014-0504-9. Erratum in: Breast Cancer Res. 2015;17(1):126.

12.

Validation of a yeast functional assay for p53 mutations using clonal sequencing.

Iggo R, Rudewicz J, Monceau E, Sevenet N, Bergh J, Sjoblom T, Bonnefoi H.

J Pathol. 2013 Dec;231(4):441-8. doi: 10.1002/path.4243.

13.

Models incorporating chromatin modification data identify functionally important p53 binding sites.

Lim JH, Iggo RD, Barker D.

Nucleic Acids Res. 2013 Jun;41(11):5582-93. doi: 10.1093/nar/gkt260. Epub 2013 Apr 17.

14.

Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations.

Rouault A, Banneau G, Macgrogan G, Jones N, Elarouci N, Barouk-Simonet E, Venat L, Coupier I, Letouzé E, de Reyniès A, Bonnet F, Iggo R, Sévenet N, Longy M.

PLoS One. 2012;7(12):e52079. doi: 10.1371/journal.pone.0052079. Epub 2012 Dec 21.

15.

New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours.

Iggo RD.

Breast Cancer Res. 2011;13(6):318. doi: 10.1186/bcr3036. Epub 2011 Dec 8.

16.

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R; EORTC 10994/BIG 1-00 Study Investigators.

Lancet Oncol. 2011 Jun;12(6):527-39. doi: 10.1016/S1470-2045(11)70094-8. Epub 2011 May 11. Erratum in: Lancet Oncol. 2013 Feb;14(2):e47.

17.

Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD.

Lancet Oncol. 2011 Feb;12(2):116. doi: 10.1016/S1470-2045(11)70011-0. No abstract available.

PMID:
21277543
18.

Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.

Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R, Bonadona V, David A, Dugast C, Gilbert-Dussardier B, Ingster O, Vabres P, Caux F, de Reynies A, Iggo R, Sevenet N, Bonnet F, Longy M.

Breast Cancer Res. 2010;12(4):R63. doi: 10.1186/bcr2626. Epub 2010 Aug 16.

19.

Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter.

Peerlinck I, Merron A, Baril P, Conchon S, Martin-Duque P, Hindorf C, Burnet J, Quintanilla M, Hingorani M, Iggo R, Lemoine NR, Harrington K, Vassaux G.

Clin Cancer Res. 2009 Nov 1;15(21):6595-601. doi: 10.1158/1078-0432.CCR-09-0262. Epub 2009 Oct 27.

20.

Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?

Bonnefoi H, Underhill C, Iggo R, Cameron D.

Eur J Cancer. 2009 Jul;45(10):1733-43. doi: 10.1016/j.ejca.2009.04.036. Epub 2009 May 26. Review.

PMID:
19477634
21.

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.

Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M.

Nat Med. 2009 Jan;15(1):68-74. doi: 10.1038/nm.1908. Epub 2009 Jan 4. Erratum in: Nat Med. 2009 Feb;15(2):220. Wirapati, Pratyakasha [corrected to Wirapati, Pratyaksha].

PMID:
19122658
22.

Therapeutic potential of replication-selective oncolytic adenoviruses on cells from familial and sporadic desmoid tumors.

Peerlinck I, Amini-Nik S, Phillips RK, Iggo R, Lemoine NR, Tejpar S, Vassaux G.

Clin Cancer Res. 2008 Oct 1;14(19):6187-92. doi: 10.1158/1078-0432.CCR-08-0410.

23.

Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.

Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V, Shen Y, Seymour LW.

Hum Gene Ther. 2008 Sep;19(9):873-86. doi: 10.1089/hum.2008.047.

PMID:
18710328
24.

p53 Mutation in histologically normal mucosa of the aero-digestive tract is not a marker of increased risk for second primary carcinoma in head and neck cancer patients.

Escher A, Piotet E, Waridel F, Iggo R, Monnier P.

Eur Arch Otorhinolaryngol. 2009 Apr;266(4):547-51. doi: 10.1007/s00405-008-0780-z. Epub 2008 Aug 8.

PMID:
18688630
25.

Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping.

Funston GM, Kallioinen SE, de Felipe P, Ryan MD, Iggo RD.

J Gen Virol. 2008 Feb;89(Pt 2):389-96. doi: 10.1099/vir.0.83444-0.

PMID:
18198369
26.

Evidence of frequent recombination among human adenoviruses.

Lukashev AN, Ivanova OE, Eremeeva TP, Iggo RD.

J Gen Virol. 2008 Feb;89(Pt 2):380-8. doi: 10.1099/vir.0.83057-0.

PMID:
18198368
27.

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD.

Lancet Oncol. 2007 Dec;8(12):1071-1078. doi: 10.1016/S1470-2045(07)70345-5. Epub 2007 Nov 19. Retraction in: Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Lancet Oncol. 2011 Feb;12(2):116.

PMID:
18024211
28.

SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene.

Merron A, Peerlinck I, Martin-Duque P, Burnet J, Quintanilla M, Mather S, Hingorani M, Harrington K, Iggo R, Vassaux G.

Gene Ther. 2007 Dec;14(24):1731-8. Epub 2007 Oct 25.

PMID:
17960161
29.

An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells.

Duss S, André S, Nicoulaz AL, Fiche M, Bonnefoi H, Brisken C, Iggo RD.

Breast Cancer Res. 2007;9(3):R38.

30.

Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays.

Takahashi M, Shimodaira H, Andreutti-Zaugg C, Iggo R, Kolodner RD, Ishioka C.

Cancer Res. 2007 May 15;67(10):4595-604.

31.
32.

Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954.

Lukashev AN, Fuerer C, Chen MJ, Searle P, Iggo R.

Hum Gene Ther. 2005 Dec;16(12):1473-83.

PMID:
16390278
33.

Targeting of autonomous parvoviruses to colon cancer by insertion of Tcf sites in the P4 promoter.

Malerba M, Nikolova D, Cornelis J, Iggo R.

Cancer Gene Ther. 2006 Mar;13(3):273-80.

PMID:
16151476
34.

RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer.

Homicsko K, Lukashev A, Iggo RD.

Cancer Res. 2005 Aug 1;65(15):6882-90.

35.

Identification of molecular apocrine breast tumours by microarray analysis.

Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R.

Oncogene. 2005 Jul 7;24(29):4660-71.

PMID:
15897907
36.

Determinants of interferon-stimulated gene induction by RNAi vectors.

Pebernard S, Iggo RD.

Differentiation. 2004 Mar;72(2-3):103-11.

PMID:
15066190
37.

Promoter-specific p53-dependent histone acetylation following DNA damage.

Kaeser MD, Iggo RD.

Oncogene. 2004 May 13;23(22):4007-13.

PMID:
15007388
39.

Regulation of p53 stability and function in HCT116 colon cancer cells.

Kaeser MD, Pebernard S, Iggo RD.

J Biol Chem. 2004 Feb 27;279(9):7598-605. Epub 2003 Dec 9.

40.

Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression.

Butticaz C, Ciuffi A, Muñoz M, Thomas J, Bridge A, Pebernard S, Iggo R, Meylan P, Telenti A.

Antivir Ther. 2003 Oct;8(5):373-7.

PMID:
14640383
41.

Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses.

Chao C, Hergenhahn M, Kaeser MD, Wu Z, Saito S, Iggo R, Hollstein M, Appella E, Xu Y.

J Biol Chem. 2003 Oct 17;278(42):41028-33. Epub 2003 Aug 8.

42.

Induction of an interferon response by RNAi vectors in mammalian cells.

Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R.

Nat Genet. 2003 Jul;34(3):263-4.

PMID:
12796781
43.

Replicating parvoviruses that target colon cancer cells.

Malerba M, Daeffler L, Rommelaere J, Iggo RD.

J Virol. 2003 Jun;77(12):6683-91.

45.
46.
47.

p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.

Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA, Iggo R, Fronza G.

Oncogene. 2001 Jun 14;20(27):3573-9.

48.

Evaluation of methods to detect p53 mutations in ovarian cancer.

Meinhold-Heerlein I, Ninci E, Ikenberg H, Brandstetter T, Ihling C, Schwenk I, Straub A, Schmitt B, Bettendorf H, Iggo R, Bauknecht T.

Oncology. 2001;60(2):176-88.

PMID:
11244334
49.

Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants.

Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD, Moriuchi T.

Carcinogenesis. 2001 Mar;22(3):515-7.

PMID:
11238194
50.

Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway.

Brunori M, Malerba M, Kashiwazaki H, Iggo R.

J Virol. 2001 Mar;75(6):2857-65.

Supplemental Content

Support Center